Boehringer Ingelheim starts clinical development of second Ablynx nanobody

April 25, 2016 News BioVox

Nanobody producer Ablynx has received an €8 million milestone payment from longtime partner Boehringer Ingelheim. The German pharmaceutical heavyweight has started a phase I clinical trial with an anti-CX3CR1 nanobody developed at Ablynx. The nanobody’s target, CX3CR1 is a G-protein coupled receptor (GPCR) difficult to address with conventional antibodies. By inhibiting CX3CR1, the activity of inflammatory immune cells can be attenuated. Currently, the therapeutic nanobody is intended for use in chronic kidney disease, an inflammatory disorder affecting 8-16% of the world’s population.

The anti-CX3CR1 nanobody is the second from the Ablynx-Boehringer collaboration to enter development, after the bispecific anti-VEGF/Ang2 nanobody started its phase I trial last January. Ablynx and Boehringer-Ingelheim started their strategic alliance in 2007 and can earn Ablynx up to €125 million in milestone payments. To date, the collaboration already earned Ablynx more than €83 million. The new program brings the total number of nanobodies in development to 7.

Avatar photo

With a local focus and global reach, the news platform BioVox shares insights into the Benelux life sciences ecosystem with readers across the world. BioVox is an independent publisher, providing its community with quality content and first-row access to interesting breakthroughs and trends in biotech, medtech, agtech, pharma, and more. We shine a spotlight on the latest news and innovations from both our partners and community.

All posts

Subscribe to the BioVox newsletter